ERBB2 and breast cancer: No substantial differences between molecular subtypes (luminal-like vs. HER2-positive) were observed.<h4>Conclusion</h4>In this small exploratory cohort, comparable uptake patterns in [<sup>68</sup>Ga]Ga-FAPI-46- and [<sup>18</sup>F]FDG-positive breast cancer lesions were observed across subtypes, underscoring the potential of [<sup>68</sup>Ga]Ga-FAPI-46 as a versatile imaging tool.